Cargando…
Metabolic Reprogramming in the Tumor Microenvironment With Immunocytes and Immune Checkpoints
Immune checkpoint inhibitors (ICIs), Ipilimumab, Nivolumab, Pembrolizumab and Atezolizumab, have been applied in anti-tumor therapy and demonstrated exciting performance compared to conventional treatments. However, the unsatisfactory response rates, high recurrence and adaptive resistance limit the...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8632143/ https://www.ncbi.nlm.nih.gov/pubmed/34858835 http://dx.doi.org/10.3389/fonc.2021.759015 |